Dyskinesias

• CLINICAL_TRIALS trial_result · 2025-12-02
  Clinical Trial Update: Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia [NA]

  This clinical trial update discusses ongoing clinical validation of DystoniaNet, a deep learning platform intended to diagnose isolated dyst…

• CLINICAL_TRIALS trial_result · 2025-08-06
  Clinical Trial Update: Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy [Phase 2, Phase 3]

  A Phase 2/3 trial of dipraglurant (ADX48621) in Parkinson disease patients on levodopa-based therapy has been terminated.

• CLINICAL_TRIALS trial_result · 2024-10-15
  Clinical Trial Update: Open-Label Extension Study of ASTORIA [Phase 2]

  Open-label extension of ASTORIA in dyskinesias has been terminated in a Phase 2 trial sponsored by Contera Pharma A/S.

• CLINICAL_TRIALS trial_result · 2021-11-23
  Clinical Trial Update: An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease [Phase 4]

  Open-label Phase 4 trial updating tolerability and exploratory efficacy of zonisamide for dyskinesias in Parkinson's disease; study suspende…

• CLINICAL_TRIALS trial_result · 2020-12-24
  Clinical Trial Update: Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease [Phase 2]

  Phase 2 clinical trial update on AQW051 assessing safety and efficacy for L-dopa induced dyskinesias in Parkinson's disease.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2020-12-23
  Clinical Trial Update: Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [Phase 2]

  Phase 2 trial evaluating modified release AFQ056 for Parkinson's patients with L-dopa induced dyskinesias has completed.

• CLINICAL_TRIALS trial_result · 2020-12-23
  Clinical Trial Update: Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [Phase 2]

  Phase 2 trial evaluating AFQ056 for L-dopa induced dyskinesias in Parkinson's patients completed.

• CLINICAL_TRIALS trial_result · 2020-12-23
  Clinical Trial Update: Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [Phase 2]

  Phase 2 long-term safety extension study update for AFQ056 in Parkinson's patients with L-dopa-induced dyskinesias.

• CLINICAL_TRIALS trial_result · 2017-07-02
  Clinical Trial Update: ACP-103 to Treat Parkinson's Disease [Phase 2]

  NINDS reports the completion of a Phase 2 trial evaluating ACP-103 for Parkinson's disease and associated dyskinesias.

• CLINICAL_TRIALS trial_result · 2016-09-22
  Clinical Trial Update: Levetiracetam Treatment of L-dopa Induced Dyskinesias [Phase 2]

  Phase 2 trial evaluating levetiracetam for L-dopa-induced dyskinesias in Parkinson disease has completed.